Strides Pharma Science Share Price Target 2025, 2026, 2030, 2040, 2050

Strides Pharma Science is an Indian medicine company situated in Bengaluru that makes and sells low-cost generic medicines in more than 100 countries. It was founded by Arun Kumar and supplies medicines to big markets like the US and Europe, as well as to developing countries. The company is known for soft gelatin capsules and other special medicines, and it makes tablets, capsules, liquids, and complex drugs. It has factories in India, the US, and Australia that are approved by the US FDA.

What is Strides Pharma Science Ltd NSE: STAR?

Strides Pharma Science is an Indian medicine company established in 1990 by Arun Kumar. It makes and sells medicines in India and many other countries. The company mainly makes generic medicines like tablets, capsules, and injections, and it is well known for soft gelatin capsules. It supplies good-quality medicines to big markets such as the US and Europe, and also to developing countries, helping people get low-cost treatment. It has several factories approved by global health bodies like the US FDA, which shows it follows strict quality rules.

Strides Pharma Science Share Price Target

Strides Pharma Science Share Price Target 2025

It is an Indian medicine company that has focused on making medicines that are safe, good in quality, and affordable for people around the world. Over the years, it has grown from a small Indian company into a well-known global medicine company. It believes that good healthcare should be available to everyone, not only to a few people. The company has expanded its business, increased its range of medicines, and reached many countries. Today, it is known for its strong factories, many types of medicines, and its effort to improve people’s health in different parts of the world. In 2025, its share price target would be ₹1108, as per stock market analysts.

Its share price would be between ₹513 to ₹1108 in 2025, as per stock market analysts.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2025	513	1108

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	530	744
February	565	760
March	581	737
April	513	722
May	615	816
June	775	914
July	861	972
August	783	935
September	786	936
October	772	978
November	870	1025
December	750	1108

Strides Pharma Science Share Price Target 2026

The company sells its medicines in more than 100 countries. It works in developed markets like the United States and Europe, and also in developing regions such as Asia, Africa, and Latin America. This wide global presence helps the company reach millions of patients with different health needs. Working in many countries also helps the company reduce risk and keep its business stable. Its global experience helps it understand local health needs better and provide the right medicines. In 2026, its share price target would be ₹1612, as per stock market analysts.

Its share price would be between ₹1074 to ₹1612 in 2026, as per stock market analysts.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2026	1074	1612

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	1074	1190
February	1090	1225
March	1125	1284
April	1147	1300
May	1165	1374
June	1178	1424
July	1190	1458
August	1225	1501
September	1268	1525
October	1290	1554
November	1353	1578
December	1458	1612

Share Price Target 2027

The main work of the company is making generic medicines. Generic medicines are low-cost medicines that work the same way as branded medicines and are just as safe and effective. These medicines help reduce treatment costs for patients and healthcare systems. Generic medicines are very important in countries where people cannot afford expensive branded drugs. It helps governments, hospitals, and patients by providing trusted medicines at lower prices. In 2027, its share price target would be ₹2101, as per stock market analysts.

Its share price would be between ₹1580 to ₹2101 in 2027, as per stock market analysts.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2027	1580	2101

Share Price Target 2028

It makes many types of medicines in different forms so that patients can use them easily. Its products include tablets, capsules, liquids, creams, ointments, nasal sprays, and injections. The company is especially known for soft gelatin capsules, which are harder to make and need special machines. These soft capsules are easier to swallow and help the medicine work better in the body. In 2028, its share price target would be ₹2566, as per stock market analysts.

Its share price would be between ₹2074 to ₹2566 in 2028, as per stock market analysts.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2028	2074	2566

Share Price Target 2029

It has a strong presence in regulated markets like the United States, Europe, and Australia, where medicine rules are very strict. To sell medicines in these countries, companies must follow strong safety and quality rules. It has invested a lot in quality systems, trained workers, and modern technology to meet these rules. Its success in these markets shows its strong focus on safety and quality. In 2029, its share price target would be ₹3017, as per stock market analysts.

Its share price would be between ₹2500 to ₹3017 in 2029, as per stock market analysts.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2029	2500	3017

Strides Pharma Science share price Target 2030

It plays an important role in developing and emerging markets where access to affordable medicines is limited. Many developing countries face problems like high disease levels and low healthcare spending. It helps by supplying low-cost medicines that still meet global quality standards. These medicines are used in hospitals, clinics, and public health programs. It supports better public health while also growing its business. In 2030, its share price target would be ₹3500, as per stock market analysts.

Its share price would be between ₹2969 to ₹3500 in 2030, as per stock market analysts.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2030	2969	3500

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	2969	3090
February	2990	3135
March	3001	3168
April	3042	3200
May	3056	3255
June	3080	3290
July	3115	3325
August	3154	3365
September	3178	3378
October	3241	3400
November	3314	3432
December	3347	3500

Share Price Target 2040

It spends money and effort on research and development to improve existing medicines and make new ones. Its research teams work on better medicine formulas, easier ways to take medicines, and improved packaging. This focus on innovation helps the company stay competitive. Research also helps in making complex medicines like soft gelatin capsules and special-release drugs. In 2040, its share price target would be ₹6220, as per stock market analysts.

Its share price would be between ₹5676 to ₹6220 in 2040, as per stock market analysts.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2040	5676	6220

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	5676	5800
February	5690	5835
March	5722	5858
April	5754	5887
May	5775	5900
June	5790	5934
July	5821	5957
August	5845	5987
September	5867	6035
October	5890	6055
November	5967	6104
December	6011	6220

Share Price Target 2050

It has also supported public health by supplying medicines for serious diseases such as HIV, tuberculosis, and malaria. These medicines are often supplied through government and international health programs. By helping with these programs, Strides improves access to treatment in low-income and high-need areas. This work shows that the company cares about people’s health, not just profits. Along with business growth, it aims to make a positive impact by supporting healthcare systems and helping fight major diseases around the world. In 2050, its share price target would be ₹9135, as per stock market analysts.

Its share price would be between ₹8552 to ₹9135 in 2050, as per stock market analysts.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2050	8552	9135

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	8552	8704
February	8585	8732
March	8611	8768
April	8632	8790
May	8658	8820
June	8687	8854
July	8700	8874
August	8725	8912
September	8758	8942
October	8787	8987
November	8825	9045
December	8856	9135

Should I buy Strides Pharma Science stock?

Year	Minimum Price (Rs)	Maximum Price (Rs)
2025	513	1108
2026	1074	1612
2027	1580	2101
2028	2074	2566
2029	2500	3017
2030	2969	3500
2040	5676	6220
2050	8552	9135

The company sells medicines in over 100 countries and makes affordable generic and special medicines. It has factories approved by the FDA and spends money on research to grow its business. It has a strong global presence and many types of medicines, which can help it keep growing over time. The stock price can go up and down in the short term, but for investors who are patient and stay invested for several years, it has good chances for long-term growth.

Strides Pharma Science earnings results

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales +	2,752	3,316	3,070	3,688	3,890	4,565	4,685
Expenses +	2,338	2,779	3,201	3,544	3,362	3,763	3,808
Operating Profit	414	537	-131	145	528	803	877
OPM %	15%	16%	-4%	4%	14%	18%	19%
Other Income +	-43	109	-112	92	-100	3,313	11
Interest	156	150	177	261	280	249	196
Depreciation	174	206	233	243	214	192	196
Profit before tax	42	289	-653	-268	-65	3,675	495
Tax %	27%	11%	-27%	-21%	45%	2%
Net Profit +	31	258	-474	-212	-94	3,598	413
EPS in Rs	4.06	29.93	-51.25	-22.44	-7.68	389.75	43.09
Dividend Payout %	345%	8%	0%	-7%	-33%	1%

Key Metrics

TTM PE Ratio	PB Ratio	Dividend Yield	Sector PE	Sector PB	Sector Div Yld
20.47	3.15	0.45%	36.65	5.78	0.59%

Peers & Comparison

Stock	PE Ratio	PB Ratio	Dividend Yield
Strides Pharma Science Ltd	2.26	3.15	0.45%
Sun Pharmaceutical Industries Ltd	39.37	5.94	0.89%
Torrent Pharmaceuticals Ltd	67.14	16.91	0.84%
Cipla Ltd	23.25	3.92	1.05%

Is Strides Pharma Science stock good to buy? (bull case & bear case)

Bull Case:

• The company has delivered a profit CAGR of ~30–35% over the last 3–5 years, driven by recovery in the US business and better product mix.
• EBITDA improved to ~₹2,300–2,400 crore annually, with EBITDA margins expanding to ~18–19%, indicating improved operating efficiency.
• Net profit increased sharply to ~₹900–1,000 crore, reflecting better cost control and normalisation of pricing pressure.
• International markets contribute ~75–80% of total revenue, led by the US and other regulated markets, supporting higher margin potential.
• The company has reduced net debt significantly, with net debt-to-equity declining to ~0.5–0.6x.
• The company has reduced debt.
• The company has a good return on equity (ROE) track record: 3 Years ROE 50.4%

Bear Case:

• The stock price is about 3 times higher than its book value.
• Promoters’ shareholding dropped slightly last quarter by 0.44%.
• The company’s sales have grown slowly, only 10.6% over the past five years.
• Promoter holding is low at 27.9%, meaning they don’t own a big part of the company.
• Promoters have pledged 44.1% of their shares, which could be risky if they need to sell.

Conclusion

It is a big Indian medicine company based in Bengaluru. It makes affordable generic and special medicines for over 100 countries, including the US, Europe, and developing countries. It is well known for soft gelatin capsules, tablets, liquids, and other complex medicines, all made in FDA-approved factories in India, the US, and Australia. Its wide range of medicines and global reach make it a good long-term investment for patient investors.

FAQs